As of 2025-12-14, the EV/EBITDA ratio of Cara Therapeutics Inc (CARA) is 0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CARA's latest enterprise value is -13.59 mil USD. CARA's TTM EBITDA according to its financial statements is -61.10 mil USD. Dividing these 2 quantities gives us the above CARA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.9x - 10.7x | 8.4x |
| Forward P/E multiples | 12.7x - 19.5x | 15.3x |
| Fair Price | (160.97) - (134.76) | (150.14) |
| Upside | -3125.7% - -2633.1% | -2922.1% |
| Date | EV/EBITDA |